ナミキ商事株式会社 医薬品及び創薬化学品の専門商社

医薬品及び創薬化学品の専門商社

検索検索

化合物検索・調査依頼・データベース提供生理・薬理活性化合物/ポジコン

Arctiin【別名:Arctii;NSC 315527;Arctigenin-4-glucoside】

HY-N0034構造式

CAS No.
20362-31-6
製品コード
HY-N0034
サプライヤー
Medchemexpress
純度
>98%
Target
Others
参考納期(在庫有りの場合)
約5-10営業日

詳細情報

FormulaC27H34O11
M.W.534.55
PathwayOthers
SolubilityDMSO: ? 5.4 mg/mL
備考Arctiin(NSC 315527), a plant lignan that can be extracted from the Arctium lappa (burdock) seeds, is a possible environmental endocrine disruptor compounds and have been shown to influence sex hormone metabolism as well as protein synthesis, steroid biosynthesis.
IC50 Value:
Target: Others
in vitro: Treatment of PC-3 cells with arctiin decreased the cell number in a concentration- and time-dependent manner in serum-containing condition. Arctiin preferentially induced cell detachment, but did not have anti-proliferation or cytotoxic effects in PC-3 cells. The arctiin-induced effect was inhibited by cycloheximide, indicating that protein synthesis was required [1]. Although arctiin, the active component of AL that has been described in the literature, was not able to reduce degranulation in RBL-2H3 cells, a single high-performance liquid chromatography (HPLC) fraction from the AL extract inhibited beta-hexosaminidase release (IC(50) = 22.2 microg/ml) [2]. The growth inhibition caused by arctiin is associated with the down-regulation of cyclin D1 protein expression. Furthermore, thearctiin-induced suppression of cyclin D1 protein expression occurs in various types of human tumor cells, including osteosarcoma, lung, colorectal, cervical and breast cancer, melanoma, transformed renal cells and prostate cancer. Depletion of the cyclin D1 protein using small interfering RNA-rendered human breast cancer MCF-7 cells insensitive to the growth inhibitory effects of arctiin, implicates cyclin D1 as an important target of arctiin [6].
in vivo: Histopathological evaluation of prostate revealed that all the rats in any group developed adenocarcinoma in dorsolateral lobe of prostate, except two rats in 0.1% arctiin treated and one rat in 0.002% arctiin treated groups without prostate adenocarcinoma development [3]. After oral administration of arctiin (30, 60, 120 mg/kgd) for three weeks, the levels of serum creatinine (Scr) and blood urea nitrogen (BUN) and 24-h urine protein content markedly decreased, while endogenous creatinine clearance rate (ECcr) significantly increased [4]. STZ-induced diabetic rats were treated witharctiin at the dosage of 60 or 40 mg/kg/day via intraperitoneal injection for 8 weeks. Blood glucose and 24-h urinary albumin content were measured, and kidney histopathological changes were monitored [5].
URLhttps://www.medchemexpress.com/Arctiin.html

お問い合わせ(下記容量以外の容量をご希望される方は右側の容量記入欄に希望容量をご記入の上お問い合わせください。)

50mg : 12,200
お問い合わせ
100mg : 19,500
お問い合わせ
10mM/1mL : 101,700
お問い合わせ
お問い合わせ
  • 参考価格となりますので、実際の御見積金額と異なる場合がございます。予めご了承くださいますようお願い致します。
  • 輸入に関する法規制チェックは、御見積のご依頼を頂いた際に行います。
    (法規制によっては、稀に供給出来ない場合がございますので、あらかじめご了承ください。)
特許権侵害物質排除ポリシー
当社では、輸入取扱にかかる化学物質中に特許物質が含まれることにより特許権の侵害が生じないよう万全を期しておりますが、本製品一覧における全ての化学物質について特許登録の有無を調査することはきわめて困難であり、特許物質が含有されている場合があり得ます。
万一、当社製品一覧中に貴社の特許を侵害する物質が含有されていると判断される場合には、お手数ではございますが当社へご一報を頂けますと幸いです。直ちに該当品を本製品一覧から削除し、取扱いを停止する措置を執るものとします。